BioCentury
ARTICLE | Financial News

With new name, Epirium snags $85M series A to develop hormonal therapy for muscular dystrophies

December 18, 2019 8:30 PM UTC
Updated on Dec 18, 2019 at 8:38 PM UTC

Ten-year-old Cardero Therapeutics Inc. relaunched Wednesday as Epirium Bio with a tranched $85 million series A led by Longitude Capital and Arch Venture Partners, IP around a new hormonal pathway as well as human proof-of-concept data for its lead candidate in muscular dystrophies.

BlueBird Ventures, Adams Street, Vertex Ventures and Longevity also participated in the round...